Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Status:
Completed
Trial end date:
2005-08-01
Target enrollment:
Participant gender:
Summary
In this Multicenter trial, we will evaluate the feasibility, toxicity, and efficacy of
treatment with 90Y Zevalin following a short course of salvage chemotherapy in patients with
relapsed/refractory intermediate grade B-cell non-Hodgkin's lymphoma.